Considering that RIP2 can induce TMZ resistance in glioma cells, we pretreated the resistant cells (T98G/TR and U87MG/TR) and RIP2‐overexpressing cells (T98G and U87MG) with NF‐κB chemical inhibitors (SC75741, SN50, and JSH‐23) and an MGMT chemical inhibitor (lomeguatrib), respectively. This evidence concerns the gene RIPK2 and central nervous system cancer.